Thomas McLain
President at RENALYTIX PLC
Net worth: 25 032 $ as of 2024-03-30
Profile
Thomas H.
McLain is the President of Renalytix Plc since 2019.
He was the Chairman, President & CEO of Nabi Biopharmaceuticals from 1998 to 2007.
He was also the President & CEO of Aspira Women's Health, Inc. in 2013-2014.
He served as an Independent Director of Eastman Chemical Co. from 2004 to 2011.
He was the Vice President of Bausch & Lomb, Inc. from 1988 to 1998.
He was the COO & General Manager of Exosome Diagnostics, Inc. from 2018 to 2019.
He is the Chairman of BioFlorida, Inc. and the CEO of Claro Scientific LLC.
McLain received his undergraduate degree from the College of the Holy Cross and his MBA from the University of Rochester Simon Business School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
RENALYTIX PLC
0.06% | 2024-04-09 | 59,150 ( 0.06% ) | 25 032 $ | 2024-03-30 |
Thomas McLain active positions
| Companies | Position | Start |
|---|---|---|
| RENALYTIX PLC | President | 2019-07-28 |
Former positions of Thomas McLain
| Companies | Position | End |
|---|---|---|
Exosome Diagnostics, Inc.
 Exosome Diagnostics, Inc. Medical/Nursing ServicesHealth Services Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. Its novel exosome-based technology platform can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. The company was founded by Wayne D. Comper, Harvey J. Barnett and James R. McCullough and is headquartered in Waltham, MA. | Chief Executive Officer | 2015-09-30 |
| ASPIRA WOMEN'S HEALTH INC. | Chief Executive Officer | 2014-04-22 |
| EASTMAN CHEMICAL COMPANY | Director/Board Member | 2011-11-30 |
Nabi Biopharmaceuticals
 Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Chief Executive Officer | 2007-02-14 |
Bausch & Lomb, Inc.
 Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY. | Corporate Officer/Principal | 1998-05-31 |
Training of Thomas McLain
| College of the Holy Cross (Massachusetts) | Undergraduate Degree |
| University of Rochester Simon Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| EASTMAN CHEMICAL COMPANY | Process Industries |
| ASPIRA WOMEN'S HEALTH INC. | Health Technology |
| RENALYTIX PLC | Technology Services |
| Private companies | 5 |
|---|---|
Bausch & Lomb, Inc.
Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY. | Health Technology |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Health Technology |
| Claro Scientific LLC | |
BioFlorida, Inc.
 BioFlorida, Inc. Miscellaneous Commercial ServicesCommercial Services BioFlorida, Inc. is an organization that represents the life science industry in Florida. The private company is based in Florida and represents over 6,700 establishments and research organizations in the biopharmaceutical, medical technology, and bioagriculture sectors, providing employment to 94,000 Floridians. The American company's initiatives aim to create a favorable business environment for the development of innovative products and technologies that enhance people's lives and bring economic benefits to the state. Nancy K. Bryan has been the CEO of the company since 2013. | Commercial Services |
Exosome Diagnostics, Inc.
Exosome Diagnostics, Inc. Medical/Nursing ServicesHealth Services Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. Its novel exosome-based technology platform can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. The company was founded by Wayne D. Comper, Harvey J. Barnett and James R. McCullough and is headquartered in Waltham, MA. | Health Services |
- Stock Market
- Insiders
- Thomas McLain
